You have no items in your shopping cart.
FGFR
Catalog No. | Inhibitor Name | FGFR | FGFR1 | FGFR2 | FGFR3 | FGFR4 | Other |
---|---|---|---|---|---|---|---|
A10080 | Ponatinib | **** | Abl,PDGFRα,VEGFR2 | ||||
A11159 | BGJ398 | **** | **** | **** | ** | VEGFR2,Lyn,Kit | |
A10137 | Nintedanib | ** | ** | ** | * | VEGFR3,VEGFR2,LCK | |
A10703 | PD173074 | ** | VEGFR2,c-Src | ||||
A11411 | Dovitinib | *** | *** | FLT3,c-Kit,VEGFR3/FLT4 | |||
A11075 | AZD4547 | **** | **** | **** | * | KDR,IGFR | |
A10715 | Danusertib | ** | Aurora A,Abl,TrkA | ||||
A10953 | Orantinib | * | PDGFRβ,Flk1 | ||||
A10254 | Brivanib | * | VEGFR2,Flk1,VEGFR1 | ||||
A10198 | Dovitinib Dilactic Acid | *** | *** | FLT3,c-Kit,VEGFR3/FLT4 | |||
A11753 | MK-2461 | ** | ** | ** | |||
A10162 | Brivanib Alaninate | * | VEGFR2,Flk1,VEGFR1 | ||||
A13211 | SSR128129E | * | VEGFR2,PDGFRβ | ||||
A11558 | SU5402 | ** | |||||
A15534 | BLU9931 | * | * | * | **** | ||
A12357 | FIIN-2 | **** | *** | ** | ** | FLT3,c-Kit,VEGFR3/FLT4 | |
A14415 | CH5183284 | *** | *** | *** | * | VEGFR2 | |
A11244 | LY2874455 | **** | **** | *** | *** | ||
A15957 | Erdafitinib | ||||||
A10508 | KW-2449 | ** | FLT3, Bcr-Abl, Aurora A, PDGFRβ, IGF-1R, EGFR | ||||
A10699 | Pazopanib HCl | * | VEGFR1, VEGFR2, VEGFR3, PDGFR, c-Kit, c-Fms | ||||
A11518 | Pazopanib | * | VEGFR1, VEGFR2, VEGFR3, PDGFR, c-Kit, c-Fms | ||||
A13111 | R 1530 | * | Chk2, KDR, FGFR, Aurora A, Cdk2, VEGFR-2, PDGFRβ | ||||
A15073 | E-3810 | *** | ** | VEGFR1, VEGFR2, VEGFR3 | |||
A15848 | FIIN-3 | *** | ** | ** | ** | ||
A15957 | Alofanib (RPT835) |
Notes:
1.Hover mouse over " " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
Catalog No. | Product Name | Application | Product Information |
---|---|---|---|
A11411 SALE |
Dovitinib (TKI-258) |
RTK inhibitor |
Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
|
A13069 SALE |
XL-228 |
IGF-1R, Aurora, FGFR, ABL, SRC inhibitor |
XL228 is a protein kinase inhibitor targeting IGF1R, the AURORA kinases, FGFR1-3, ABL and SRC family kinases. XL228 is an Aurora A inhibitor (IC50, f3 nmol/L) that has shown potent biochemical activity against ABL1 (Ki, 5 nmol/L), as well as the BCR-ABL1 T315I (Ki, 1.4 nmol/L) kinases.
|
A13111 SALE |
R1530 |
Chk2, KDR, FGFR, Aurora A & Cdk2 inhibitor |
R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2.
|
A13211 |
SSR128129E |
FGFR1 inhibitor |
SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 uM
|
A14415 |
Debio-1347 (CH5183284) |
FGFR1/2/3 inhibitor |
Debio-1347 is an orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and 3 (FGFR-3), with potential antineoplastic activity.
|
A14431 SALE |
ACTB-1003 |
FGFR1 inhibitor |
ACTB-1003 is an oral kinase inhibitor targeting cancer mutations (FGFR inhibition), angiogenesis (inhibition of VEGFR2 and Tie-2) and induces apoptosis (targeting RSK and p70S6K, downstream of PI3 kinase).
|
A15073 |
E-3810 |
VEGFR/FGFR Inhibitor |
E-3810 is a potent and selective dual inhibitor of VEGF and FGF receptors with IC50 values of 7 nM, 25 nM, 10 nM, 17.5 nM and 82.5 nM for VEGFR-1, VEGFR-2, VEGFR-3, FGFR-1 and FGFR-2, respectively.
|
A15194 |
NVP-BGJ398 phosphate |
FGFR Inhibitor |
NVP-BGJ398 phosphate is a novel selective, pan-specific FGFR inhibitor with IC50 of 0.9, 1.4, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively; >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes.
|
A15534 SALE |
BLU9931 |
FGFR inhibitor |
BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM),
|
A12357 SALE |
FIIN-2 |
FGFR Inhibitor |
FIIN-2 is an irreversible inhibitor of FGFR1-4 with IC50 values of 3.1, 4.3, 27, and 45 nM, respectively.
|
A15848 |
FIIN-3 |
Irreversible FGFR inhibitor |
FIIN-3 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor.
|
A15946 |
Alofanib (RPT835) |
FGFR2 Inhibitor |
Alofanib is a potent and selective allosteric inhibitor of FGFR2 with potential anticancer activity.
|
A15957 |
Erdafitinib (JNJ-42756493) |
FGFR inhibitor |
Erdafitinib is a potent and selective orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity.
|
A16197 |
Nintedanib esylate |
RTK inhibitor |
Nintedanib is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).
|
A16251 |
FGFR4-IN-1 |
FGFR4 inhibitor |
FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 0.7 nM.
|
A11558 SALE |
SU-5402 |
VVEGFR/FGFR/EGFR inhibitor |
SU-5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor (IC50 values are 0.02, 0.03, 0.51 and > 100 μM at VEGFR2, FGFR1, PDGFRβ and EGFR respectively).
|
A11244 SALE |
LY 2874455 |
FGFR/VEGFR2 inhibitor |
LY2874455 is a novel and potent FGFR/VEGFR Inhibitor.
|
A10080 SALE |
AP24534 (Ponatinib) |
BCR-ABL inhibitor |
AP24534 (Ponatinib) is a potent multi-kinase and pan-BCR-ABL inhibitor.
|
A10715 SALE |
Danusertib (PHA-739358) |
Aurora inhibitor |
Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2
|
A10137 SALE |
Bibf1120 (Vargatef) |
VEGFR inhibitor |
BIBF1120 (Vargatef) is a novel triple angiokinase inhibitor that inhibits three growth factor receptors simultaneously: VEGFR, PDGF and FGFR.
|
A10703 SALE |
PD173074 |
FGFR1/VEGFR2 Inhibitor |
PD173074 is a potent, cell permeable and ATP competitive inhibitor of FGFR and VEGFR.
|
A10953 SALE |
TSU-68 (Orantinib, SU6668) |
PDFGRβ inhibitor |
Orantinib (TSU-68, SU6668) has greatest potency against PDGFR autophosphorylation with Ki of 8 nM in a cell-free assay, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR. Phase 3.
|
A10254 SALE |
Brivanib (BMS-540215) |
VEGFR-2 inhibitor |
Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
|
A10162 |
Brivanib alaninate (BMS-582664) |
VEGFR inhibitor |
Brivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
|
A10508 SALE |
KW-2449 |
FLT3/FGFR/Bcr-Abl/Aurora Inhibitor |
KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
|
A11075 SALE |
AZD4547 |
FGFR inhibitor |
AZD4547 is a potent, selective and orally active pan-FGFR inhibitor, with IC50s of 0.2, 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively.
|
A11159 SALE |
BGJ398 (NVP-BGJ398) |
FGFR Inhibitor |
BGJ398 is a potent and selective inhibitor with potential antiangiogenic and antineoplastic activities of fibroblast growth factor receptor (FGFR) tyrosine kinases 1, 2, 3 and 4 (with IC50 values of 0.9, 1.4, 1.0 and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4 respectively).
|
A10699 SALE |
Pazopanib HCl (GW786034) |
VEGFR/PDGFR/FGFR inhibitor |
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
|
A10198 SALE |
Dovitinib Dilactic acid (TKI258 Dilactic acid) |
RTK inhibitor |
Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
|
A11753 |
MK-2461 |
c-Met Inhibitor |
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
|
A11518 SALE |
Pazopanib (GW-786034) |
VEGFR inhibitor |
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
|
A16252 |
H3B-6527 |
FGFR4 inhibitor |
H3B-6527 is a highly selective FGFR4 inhibitor with potent antitumour activity in FGF19 amplified cell lines and mice.
|